Brief: Gentian Diagnostics Q4 EBITDA NOK 10.5 Million
11/02/2026 07:24
Feb 11 (Reuters) - Gentian Diagnostics ASA GENT.OL: Q4 EBITDA NOK 10.5 MILLION Q4 SALES OF NOK 46.6 MILLION, UP 9% Y/Y BOARD PROPOSES A DIVIDEND OF NOK 0.60 PER SHARE Q4 GROSS MARGIN OF 58% Source text: ID:nObi4xQCsa Further company coverage: GENT.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Gentian Diagnostics ASA
See all newsBrief: Essange Reagents And Gentian Diagnostics Announce Collaboration Agreement
Brief: Gentian Diagnostics: Vatne Capital Reduces Indirect Ownership
Brief: Gentian Diagnostics Renews Long-Term Partnership With Bühlmann Laboratories
Brief: Gentian Diagnostics Q4 EBITDA NOK 10.5 Million
Brief: Gentian Diagnostics Enters Exclusive Agreement With Global Diagnostics Company